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Abstract
Background: The Asia-Pacific region is home to nearly half of the world’s population. The region has seen a recent
rapid increase in the prevalence of obesity, type-2 diabetes and cardiovascular disease. The present systematic
review summarizes the recent prevalence and trends of Metabolic Syndrome (MetS) among adults in countries of
the Asia-Pacific Region.
Methods: Data on MetS in Asia-Pacific countries were obtained using a stepwise process by searching the online
Medline database using MeSH terms ‘Metabolic Syndrome X’ and ‘Epidemiology/EP’. For the purpose of describing
prevalence data for the individual countries, studies that were most recent, nationally representative or with the
largest sample size were included. When evaluating secular trends in prevalence in a country we only considered
studies that evaluated the temporal change in prevalence between similar populations, prospective studies based
on the same population or National surveys conducted during different time periods.
Results: This literature search yielded a total of 757 articles, and five additional article were identified by screening
of reference lists. From this total, 18 studies were eligible to be included in the final analysis. Of the 51 Asia-Pacific
countries (WHO) we only located data for 15. There was wide between country variation in prevalence of MetS.
A national survey from Philippines conducted in 2003 revealed the lowest reported prevalence of 11.9% according
to NCEP ATP III criteria. In contrast, the highest recorded prevalence in the region (49.0%) came from a study
conducted in urban Pakistan (Karachchi, 2004). Most studies reported a higher prevalence of MetS in females and
urban residents. Data on secular trends were available for China, South Korea and Taiwan. An increase in the
prevalence of MetS was observed in all three countries.
Conclusion: Despite differences in methodology, diagnostic criteria and age of subjects studied, the Asia-Pacific
region is facing a significant epidemic of MetS. In most countries nearly 1/5th of the adult population or more
were affected by MetS with a secular increase in prevalence. Strategies aimed at primary prevention are required
to ameliorate a further increase in the epidemic and for the reduction of the morbidity and mortality associated
with MetS.
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Background
Since being first described by Gerald M. Raevan in the
1980s numerous definitions and diagnostic criteria have
been coined for Syndrome X (also known as metabolic
syndrome) [1]. The International Diabetes Federation
(IDF), National Cholesterol Education Program Adult
Treatment Panel – III (NCEP ATP-III) guidelines and
many others have defined metabolic syndrome (MetS) as
a cluster of inter-connected metabolic abnormalities in-
volving glucose metabolism (diabetes mellitus), lipid me-
tabolism (hypercholesterolaemia and dyslipidaemia),
elevated blood pressure and central obesity [2]. MetS
increases the risk of type-2 diabetes, cardiovascular
disease and all cause mortality [3]. It is also related to
other co-morbidities including, pro-thrombotic and pro-
inflammatory states, non-alcoholic steatohepatitis and
reproductive disorders. Furthermore, the association of
MetS with certain types of cancers is increasingly de-
scribed in the literature [4].
The pathophysiology of MetS is complex with insulin
resistance and abnormal regulation of lipid metabolism
playing a central role in pathogenesis [5, 6]. Genetic pre-
disposition is a factor in MetS, and prevalence differs
among ethnic groups [7]. Some studies have demon-
strated heritability of up to 70% involving HDL genes
[8]. Age, lifestyle factors and socioeconomic status also
play a major role in the pathogenesis [3]. Studies asses-
sing the prevalence of MetS report conflicting results
due to variations in diagnostic criteria. However, irre-
spective of the criteria used it is well accepted that the
prevalence of MetS is increasing in epidemic proportions
in both developed and developing countries globally [3].
The worldwide prevalence of MetS in the adult popula-
tion is estimated to be 20–25% [9]. This rapid increase
in MetS has been paralleled by the growing epidemic of
type-2 diabetes, hypertension, cardiovascular disease and
obesity [10].
The Asia-Pacific region typically includes much of
Southeast Asia, and Oceania [11]. Countries in the re-
gion have a wide diversity in socio-cultural background
and are at different levels of economic and technological
development. Increasing economic development in
many of the lower to middle-income countries of the re-
gion has been a major contributor to the increasing
prevalence of obesity, type-2 diabetes and cardiovascular
disease [12–14]. Hence, it is likely that the prevalence of
MetS has also increased in the region in recent years.
Several systematic reviews and meta-analyses on the
prevalence of MetS have been published on South and
East Asian populations [15]. However to date no studies
have evaluated the prevalence of MetS in the Asia-
Pacific region. Identification of the regional disease
burden and trends will enable the prioritization and im-
plementation of interventions through existing regional
collaborations. The present systematic review summa-
rizes the recent prevalence and trends of MetS among
adults in countries of the Asia-Pacific Region.
Methods
The systematic review was performed following the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines and the PRISMA
checklist is provided as a (Additional file 1).
Search strategy
Data on MetS in Asia-Pacific countries were obtained
using a stepwise process. We began our literature review
by searching the online Medline database (Medical Lit-
erature Analysis and Retrieval System) using MeSH
(Medical Subject Heading) term ‘Metabolic Syndrome X’
as a MeSH major topic and Epidemiology/EP as a MeSH
subheading. The search comprised studies listed up to
30th of April 2016. The search limits were; language
(‘English’), Species (‘Humans’) and age (‘all adults: 19+
years’). The conjunction of the above results were nar-
rowed down by including the names of the individual
Asia-Pacific countries as defined by the World Health
Organization (Afghanistan, American Samoa, Australia,
Bangladesh, Bhutan, Brunei Darussalam, Cambodia,
China, Cook Islands, Democratic People's Republic of
Korea, Fiji, French Polynesia, Guam, Hong Kong, India,
Indonesia, Japan, Kiribati, Lao, Macau, Malaysia, Maldives,
Marshall Islands, Micronesia, Mongolia, Myanmar, Nauru,
Nepal, New Caledonia, New Zealand, Niue, Northern
Mariana Islands, Pakistan, Palau, Papua New Guinea,
Philippines, Pitcairn Islands, Republic of Korea, Samoa,
Singapore, Solomon Islands, Sri Lanka, Taiwan, Thailand,
Timor-Leste, Tokelau, Tonga, Tuvalu, Vanuatu, Vietnam
and, Wallis and Futuna) [16]. In stage two the total num-
ber of articles obtained from searching the Medline data-
base utilizing the search criteria defined above, were
screened for suitability for inclusion by reading the article
‘title’ and ‘abstract’. The studies not meeting with inclusion
criteria (defined below) were removed during stage two.
The remaining studies were further screened for suitability
during the third stage by reading the full-text of the se-
lected manuscript. To obtain additional data, a manual
search was performed using the reference lists of selected
articles. This process was conducted by two independent
reviewers (PR and YM) and the final group of articles to
be included in the review was determined after an iterative
consensus process among the reviewers.
Inclusion/Exclusion criteria and definitions
The following inclusion criteria were applied: a)
population-based studies among healthy non-institu-
tionalized adults, assessing the prevalence of MetS, de-
fined by an accepted definition (as mentioned below), b)
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studies conducted in adults aged ≥ 18 years, c) cross‐sec-
tional study design or being the first phase of a longitu-
dinal study (prospective follow-up studies), d)
geographically and temporally defined population from
any of the Asia-Pacific regional countries mentioned
above, e) studies published in English or with detailed
summaries and f) studies published before 30th April
2016. Studies were excluded based on the following exclu-
sion criteria: being confined to only a specific age/patient/
community/ethnic group, being hospital/clinic-based,
studies reporting the results of larger studies as duplica-
tions and studies conducted among Asians residing else-
where. In addition during the final analysis most
individual studies have excluded subjects with incom-
plete data for components of MetS.
Presence of ‘Metabolic Syndrome’ in the individual
studies were considered only if defined according to one
of the following accepted criteria; a) International Dia-
betes Federation (IDF) criteria, b) National Cholesterol
Education Programme’s Adult Treatment Panel III cri-
teria (NCEP/ATP III), c) modified IDF and modified
NCEP/ATP III criteria with Asian cutoffs for Body Mass
Index (BMI) and waist circumference, d) American
Heart Association/National Heart, Lung and Blood Insti-
tute (AHA/NLHBI) criteria, or f ) a harmonized criteria
adopted at the time of the respective studies. The differ-
ent definitions used in the respective studies are summa-
rized in Table 1.
Data extraction and analysis
One reviewer was responsible for the extraction of data
from the included articles, by using a standardized form.
A second reviewer checked the accuracy of the data ex-
tracted. The following details were extracted from each
study: a) details of the study (country/city, year of publi-
cation/year of survey and setting of the study), b) study
methods (sample size, sampling method, age of the sub-
jects in years and definition of MetS used in the study),
and c) MetS prevalence data (for all adults, males and fe-
males). Any discrepancies in the data extracted in this
manner were re-checked and resolved by discussion. A
third reviewer was also involved where necessary.
Data not presented in the published manuscript (gen-
der and area-specific prevalence) were obtained by con-
tacting the corresponding author, or where possible
calculated from the available data. When describing the
prevalence of MetS for an individual country, the study
that was the most recent, nationally representative or
that had the highest sample size was selected. The age-
standardized data is described here (unless stated other-
wise), to enable for a meaningful comparisons between
countries. When exploring the secular trends in preva-
lence of MetS in an individual country we only consid-
ered studies evaluating temporal changes between the
same/similar populations or national surveys conducted
at different times. As described above, only the age-
standardized prevalence was considered when evaluating
secular trends.
Results
This literature search yielded a total of 757 articles
(China - 178, Japan - 172, South Korea - 125, India - 90,
Taiwan - 75 and others – 54). Screening of reference
lists of the included articles identified five additional ar-
ticles. After removing duplicates, 621 articles remained.
The title and abstract of these papers were screened to
identify potentially relevant papers for full review. The
full text was obtained for 199 papers deemed to be po-
tentially relevant. From this total, 18 studies were eligible
to be included in the final analysis. The summary of the
search strategy is presented in Fig. 1. Of the 51 Asia-
Pacific countries (WHO) we only located data for 15
counties (Australia, China, India, Indonesia, Japan, South
Korea, Macau, Malaysia, Mongolia, Pakistan, Philippine,
Table 1 Diagnostic criteria used in the different studies
Organization Diagnostic Criteria
International Diabetes
Federation (IDF)
Central obesity with waist circumference≥
90 cm for males and≥ 80 cm for females, plus
two or more of the following:
1. Systolic blood pressure≥ 130 mmHg or
diastolic blood pressure≥ 85 mmHg or
antihypertensive medication;
2. Fasting plasma glucose≥ 5.6 mmol/L or
previously diagnosed type 2 diabetes;
3. Plasma HDL cholesterol < 1.03 mmol/L for
males and < 1.29 mmol/L for females;
4. Plasma triglycerides ≥ 1.7 mmol/L
National Cholesterol.
Education Program,
Adult Treatment
Panel III (NCEP ATP III)
Three or more of the following:
1. waist circumference ≥ 102 cm for males
and≥ 88 cm for females;
2. systolic blood pressure≥ 130 mmHg or
diastolic blood pressure≥ 85 mmHg or
antihypertensive medication;
3. fasting plasma glucose≥ 5.6 mmol/L or on
medication for high blood glucose;
4. HDL cholesterol <1.03 mmol/L for males
and <1.30 mmol/L for females;
5. triglycerides≥ 1.7 mmol/L
Revised NCEP ATP III
Criteria for Asians
Same as NCEP ATP III (above) with a modified
waist circumference cut-off for Asians of ≥
90 cm for males and≥ 80 cm for females
An American Heart
Association/National
Heart, Lung, and
Blood Institute
(AHA/NHLBI)
Three or more of the following:
1. waist circumference ≥ 102 cm for males
and≥ 88 cm for females (for Asians≥ 90 cm
for males and≥ 80 cm for females);
2. systolic blood pressure≥ 130 mmHg or
diastolic blood pressure≥ 85 mmHg or
antihypertensive medication;
3. fasting plasma glucose≥ 5.6 mmol/L or on
medication for high blood glucose;
4. HDL cholesterol <1.03 mmol/L for males and
<1.30 mmol/L for females or on medications
for reduced HDL cholesterol;
5. triglycerides≥ 1.7 mmol/L or on medications
for elevated triglycerides
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Singapore, Sri Lanka, Taiwan and Vietnam). The search
revealed national surveys for 9 countries. Where na-
tional studies were not available the most recent regional
study with the largest sample was selected (Australia,
India, Indonesia, Japan, Pakistan and Vietnam), of which
4 studies were in urban settings and the remaining stud-
ies were in rural setting. Majority of the studies used a
combination of definitions for MetS (n = 6), while five
studies used the revised NCEP ATP III criteria and four
studies used the IDF criteria. The remaining three stud-
ies used the NCEP ATP III criteria. The sample size
ranged from 363 (an urban study in Pakistan) to 47325
(a national study in China). Majority of the studies in-
cluded adults (>18 years in most and >20 years in few),
without defining any upper limit for age, whilst in
the remaining studies the included age group varied
considerably.
Prevalence of metabolic syndrome
The prevalence of MetS in the respective countries and
the sample characteristics are summarized in Table 2.
Almost all surveys reported prevalence data not only for
all adults but also for males and females separately.
There was wide between country variation in prevalence
of MetS. A national survey from Philippines conducted
in 2003 revealed the lowest reported prevalence of 11.9%
according to NCEP ATP III criteria [17]. In contrast, the
highest recorded prevalence in the region (49.0%) came
from a study conducted in urban Pakistan (Karachchi,
2004) [18]. The next highest prevalence was reported
from Malaysia (37.1%) (IDF criteria) [19]. The highest
prevalence from a National survey was also reported
from the same survey done in Malaysia in 2008 (37.1%,
IDF criteria), in year 2008 [19]. The most recent preva-
lence was 31.3% (modified NCEP-ATP III), observed in
a National survey conducted in South Korea in 2011–
2012 [20]. Data from four National surveys were avail-
able in China, with the most recent survey (2009)
reporting a prevalence of 21.3% (NCEP ATP III) [21].
Most studies reported a higher prevalence of MetS in
females, except in studies conducted in rural Australia
[22], rural India [23], urban Japan [24], urban Pakistan
[18] and one National survey conducted in China [25]
and Macau [26]. The highest prevalence in females
(47.2%, IDF criteria) was observed in a study conducted
in urban India [27], while the lowest prevalence (3.7%,
IDF criteria) was observed in a National survey con-
ducted in Macau [26]. A study conducted in urban
Pakistan reported the highest prevalence of MetS in
males (55.6%, modified NCEP ATP III criteria) [18]. The
lowest prevalence in males was observed in two national
surveys conducted in the Philippines (10.5%, NCEP ATP
III criteria) and Macau (10.5%, IDF criteria) [17, 26]. An
urban and rural comparison of MetS prevalence was
available from five National surveys conducted in China,
Malaysia, Mongolia and Sri Lanka [19, 28–31]. In all but
the Mongolian study, urban adults had a higher preva-
lence of MetS, in comparison to the rural counterparts,
Fig. 1 Summarized search strategy
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irrespective of the MetS definition used (NCEP ATP III
or IDF criteria) (Table 3).
Secular trends in prevalence
Area of residence is a key factor determining the preva-
lence of MetS; therefore, when exploring secular trends
in prevalence we only considered studies that evaluated
the temporal change in prevalence between similar pop-
ulations, prospective studies based on the same popula-
tion or data resulting from National surveys conducted
during different time periods. Such data were available
for China, South Korea and Taiwan (Table 4) [21, 28, 32,
33]. An increase in the prevalence of MetS was observed
in all three countries. The Korean National Health and
Nutrition Examination Survey (KNHANES) survey re-
ported a steady increase in the crude prevalence of the
MetS in Korea from 24.9% in 1998 to 31.3% in 2007 ac-
cording to the modified NCEP ATP III criteria [32]. A
national survey in Taiwan using the modified NCEP/
ATP III criteria also showed a significant increase in the
prevalence of MetS from 13.6% (1993–1996) to 25.5%
(2005–2008) over a period of 10–15 years [33]. A similar
result was observed in China (13.7%, 2000–2001 and
21.3%, 2009) [21, 28]. These observations were also
noted independently in males and females (Fig. 2).
Discussion
This is the first comprehensive report to systematically
evaluate the scientific literature on the prevalence and
trends for MetS in the Asia-Pacific region. Prevalence,
based on the most recent national surveys in the coun-
tries of the region ranged from 11.9% in Philippines
(2003) to 37.1% in Malaysia (2008). In most countries
nearly 1/5th of the adult population or more were af-
fected by MetS, comparable with the IDF estimation that
nearly one quarter of the world’s adult population is suf-
fering from MetS [34]. Data are comparable with other
regions of the world (Table 5) and indicates a secular in-
crease in prevalence in the region. Despite differences in
methodology, diagnostic criteria and age of subjects
studied, the Asia-Pacific region is facing a significant
epidemic of MetS. Hence strategies aimed at primary
prevention are required to ameliorate a further increase
Table 2 Prevalence of metabolic syndrome
Country Study details (Study date; Study setting;
Sample size; Age group)
Metabolic Syndrome
definition
Prevalence of metabolic syndrome [95% CI]
All adults Males Females
Australia [22] 2004–2006; Rural; N – 1563; 25–74 years IDF 35.8ab [NR] 39.0b [NR] 33.0b [NR]
China 2009; National; N – 7488; > 18 years NCEP ATP III 21.3 [20.4–22.2] 20.9 [19.5–22.2] 21.7 [20.4–23.0]
IDF 18.2 [17.3–19.1] 16.2 [15.0–17.4] 20.0 [18.8–21.2]
India [23, 27] 2005; Rural; N – 4535; > 30 years NCEP ATP III 24.6 [21.7–27.5]b 26.9 [24.3–32.9]a 18.4 [16.7–24.1]a
2007; Urban; N – 2225; > 20 years NCEP ATP III 16.9 [NR] 27.7b[NR] 43.2b [NR]
IDF 19.4 [NR] 31.8b [NR] 47.2b [NR]
Indonesia [42] 2006; Urban; N – 1591; 25–64 years Modified NCEP ATP III 28.4b [NR] 25.4b [NR] 30.4b [NR]
Japan [24] 2004; Urban; N – 2321; 40–87 years NCEP ATP III 16.5b [NR] 17.2b [NR] 16.0b [NR]
Macau [26] 2006; National; N – 1592; 18–44 years IDF NR 10.5 [NR] 3.7 [NR]
Malaysia [19] 2008; National; N – 4341; > 18 years NCEP ATP III 34.3b [32.9–35.8] 31.1b [28.8–33.5] 36.1b [34.3–37.9]
IDF 37.1b [35.6–38.5] 32.1b [29.8–34.5] 39.8b [38.0–41.6]
Mongolia [31] 2009; National; N – 1911 > 40 years IDF 32.8b [NR] 19.2b [NR] 40.9b [NR]
Pakistan [18] 2004; Urban; N – 363; > 25 years IDF 34.8 [29.7–39.9] 31.8 [22.7–40.9] 36.1 [29.9–42.3]
Modified NCEP ATP III 49.0 [43.8–54.1] 55.6 [46.5–64.7] 45.9 [39.7–52.1]
Philippine [17] 2003;National; N – 4753; > 20 years NCEP ATP III 11.9 [10.6–13.2] 10.5 [8.8–12.2] 13.4 [11.6–15.2]
IDF 14.5 [13.1–16.0] 11.8 [10.1–13.6] 17.4 [15.3–19.5]
Singapore [43] 1998; National; N – 4723; 18–69 years IDF 20.2 [NR] NR NR
AHA/NHLBI 26.9 [NR] NR NR
South Korea [20] 2011–2012; National; N – 9650; > 19 years AHA/NLHBI 31.3a [NR] NR NR
Sri Lanka [30] 2005–2006; National; N – 4485; > 18 years IDF 24.3 [23.0–25.6] 18.4 [16.5–20.3] 28.3 [26.6–30.0]
Taiwan [33] 2005–2008; National; N – 2787; > 18 years Modified NCEP ATP III 25.5 [NR] 25.5ab [NR] 31.5ab [NR]
Vietnam [44] 2011; Rural; N – 2443; 40–64 years Modified NCEP ATP III 16.3 [14.0 − 18.6] 13.9 [11.5 − 16.2] 18.5 [16.3 − 20.7]
CI Confidence Interval, NR Not Reported
aCalculated using the available data; bCrude Prevalence
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in the epidemic and for the reduction of the morbidity
and mortality associated with MetS.
The Asia-Pacific region is home to more than half of
the world’s population and includes some of the world’s
richest alongside some of the poorest and least devel-
oped countries [35]. Despite persistent levels of under-
weight in some countries, overweight, obesity and
associated non-communicable diseases have become a
major public health concern for the entire region [35].
The increased prevalence of MetS in the region could be
attributed to regional changes in disease patterns from
communicable to non-communicable diseases, resulting
from increased life expectancy, rapid population growth
and unplanned urbanization [36]. This ‘epidemiological
transition’ is closely linked to the rapid industrialization
occurring in the region, as evidenced by the higher
prevalence of MetS observed among urban residents.
Unhealthy lifestyle changes associated with urbanization
such as physical inactivity, changes in diet and stress, are
likely associated with increased risk of MetS. Rural-to-
urban migration is also known to be a major factor in
the epidemiology of non-communicable diseases, includ-
ing diabetes and obesity [37]. Migrants typically change
their lifestyles considerably within a short period of time
and physical activity status quickly reaches urban levels
with acquisition of a metabolic risk similar to that of
urban dwellers [37]. Our results also show that the
prevalence of MetS is also rising in rural communities of
the Asia-Pacific. Increased mechanization of the agricul-
ture industry, automation of daily activities, popularization
of television and increased computer usage in rural areas
are leading to changes in lifestyle with resultant decreases
in physical activity [38].
Parallel to the increase in MetS and obesity, the preva-
lence of associated non-communicable diseases such as
diabetes is also rising in the region. It is estimated that the
region has more than 138 million people with diabetes, a
number which is expected to rise to 200 million by 2035
[39]. Hence, the MetS epidemic and associated non-
communicable diseases are a significant public health con-
cern in the region at present. It is important to look at
shared risk factors in order to develop harmonized
universal preventive strategies, through existing regional
collaborations. Physical inactivity/sedentary life style,
urban residency, smoking, alcohol consumption, family in-
come and level of education are some of the modifiable
factors identified as associated with MetS from the studies
included in the present review. Increasing age, female gen-
der and family history of diabetes were some of the other
non-modifiable factors associated with the presence of
MetS. Due to the limited number of studies or due to vari-
ations in definitions/classifications of risk factors between
studies a meta-analysis and quantification of the strength
of association could not be performed.
Table 3 Urban and rural prevalence of metabolic syndrome
Country Study details (Study date; Study setting; Sample size; Age group) Metabolic Syndrome definition Urban [95% CI] Rural [95% CI]
China [28, 29] 2000–2001; National; N – 15540; 35–74 years NCEP ATP III 18.6 [17.6–19.6] 12.7 [10.7–13.1]
2007–2008; National; N – 47325 > 20 years IDF 26.5 [NR] 22.1 [NR]
Malaysia [19] 2008; National; N – 4341; > 18 years NCEP ATP III 36.0a [33.9–38.0] 32.6a [30.6–34.6]
IDF 39.1a [37.1–41.2] 35.0a [33.0–37.1]
Mongolia [31] 2009; National; N – 1911≥ 40 years IDF 31.7a [NR] 34.1a [NR]
Sri Lanka [30] 2005–2006; National; N – 4485; > 18 years IDF 34.8 [31.8–37.9] 21.6 [20.2–23.0]
CI Confidence Interval, NR Not Reported
aCrude Prevalence
Table 4 Secular trend in prevalence of metabolic syndrome
Country Study details (Study date; Study setting;
Sample size; Age group)
Metabolic Syndrome
definition
Prevalence of Metabolic Syndrome [95% CI]
All adults Males Females
China [21, 28] 2000–2001; National; N – 15540; 35–74 years NCEP ATP III 13.7 [12.9–14.5] 9.8 [9.0–10.6] 17.8 [16.6–19.0]
2009; National; N – 7488; ≥ 18 years NCEP ATP III 21.3 [20.4–22.2] 20.9 [19.5–22.2] 21.7 [20.4–23.0]
South Korea [32] 1998; National; N – 6907; >20 years Modified NCEP ATP III 24.9 [23.7–26.1]a 22.4 [19.8–24.9]a 27.9 [25.5–30.2]a
2001; National; N −4536; > 20 years Modified NCEP ATP III 29.2 [27.8–30.5]a 26.9 [24.5–29.2]a 31.8 [29.1–34.5]a
2005; National; N – 5373; > 20 years Modified NCEP ATP III 30.4 [29.2–31.6]a 31.7 [28.8–34.6]a 29.5 [26.6–32.4]a
2007; National; N – 2890; > 20 years Modified NCEP ATP III 31.3 [30.1–32.5]a 29.0 [25.9–32.1]a 32.9 [29.4–36.4]a
Taiwan [33] 1993–1996; National; N – 2860; > 18 years Modified NCEP ATP III 13.6 [NR] 13.6 [NR] 26.4 [NR]
2005–2008; National; N – 2787; > 18 years Modified NCEP ATP III 25.5 [NR] 25.5 [NR] 31.5 [NR]
CI Confidence Interval, NR Not Reported
aCalculated using the available data
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However, of the 51 countries in the Asia-Pacific re-
gion, data on MetS was available for only 15 countries.
Future, well-designed epidemiological studies with rep-
resentative population samples would provide the basis
for a better understanding of the extent and public
health implications of MetS in the region. Such studies
would also help to develop standardized measurement cri-
teria and definitions of MetS, to allow meaningful com-
parisons within and between populations. Furthermore,
the actual health care costs and economic burden of MetS
in the Asia-Pacific region have not been assessed to date.
It is necessary to conduct future studies to assess the dir-
ect and indirect costs of MetS in countries of the region.
Such studies need to focus on standardized calculation
methods to make meaningful between country compari-
sons. Future research also needs to focus on identification
of shared risk factors for MetS. However, as highlighted
previously such studies need to be conducted in a
Fig. 2 Secular trends in Prevalence in, a) Males and b) Females
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prospective sample, using standard definitions for risk fac-
tors. Regional organizations such as the WHO could play
an important role in introducing such assessment stan-
dards for future research conducted in the region.
The strengths of the current systematic review are the
comprehensive and easily replicable search strategy ap-
plied and the selection of studies through the application
of well-defined inclusion/exclusion criteria. We would
also like to highlight several limitations in the present
review. There was no uniformity of MetS definition, age
groups, waist circumference cut-offs, and study settings
in the studies included in the present review, resulting in
limitations in comparability. There were four definitions
of MetS primarily used in the studies included in the
present analysis (IDF criteria, NCEP ATP III, revised
NCEP ATP III and AHA/NLHBI). The main difference
between the IDF criteria and the other 3 criteria is that
the IDF requires the presence of abdominal obesity (de-
fined by waist circumference) as an essential factor for
defining MetS, whilst in the other criteria it is not an es-
sential requirement [40]. Since, Asians are known to de-
velop metabolic complications at lower thresholds for
abdominal obesity most criteria separately define central
obesity cut-offs for Asians and other populations. This
difference has been taken into account by most studies
included in the present analysis. However, even in West-
erners in the NCEP ATP III criteria, a difference of
14 cm in current abdominal obesity criteria across gen-
ders may be debatable, leading to dilution of MetS in
women or a failure of encompassing men with MetS at
increased cardio-metabolic risk [41]. It is very well
known that the prevalence of MetS varies and depends
on the criteria used in different definitions, as well as
the composition (sex, age, race and ethnicity) of the
population studied. Hence, the differences in the defini-
tions used in the studies included in the present analysis
makes it difficult for meaningful comparisons between
countries. However, it is generally accepted that no mat-
ter which criteria are used, the prevalence of MetS is
high and rising in most counties as a result of the obes-
ity epidemic [41]. Furthermore, most studies included in
the present analysis are nearly 5–10 years old, hence the
current prevalence of MetS in the region and the associ-
ated disease burden is likely to be much higher. For ex-
ample, the most recent national prevalence study in
South Korea approximately 5 years ago observed a
prevalence of 31.3%. Countries for which data on secular
trends are available have shown an increase in preva-
lence of about 50–75% over a period of 10 years,
highlighting the need for newer well-designed epidemio-
logical studies to identify the most recent extent of the
MetS epidemic in the Asia-Pacific region.
Conclusions
Despite differences in methodology, diagnostic criteria
and age of subjects studied, the Asia-Pacific region is fa-
cing a significant epidemic of Metabolic Syndrome. In
most countries nearly 1/5th of the adult population or
more were affected by Metabolic Syndrome with a secu-
lar increase in prevalence. Hence regional strategies
through existing collaborative partnerships aimed at
primary prevention are required to ameliorate a further
increase in the epidemic and for the reduction of the
morbidity and mortality associated with Metabolic
Syndrome.
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